Dermatology Lab · DeCure for X
DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for dyskeratosis congenita, autosomal recessive 5 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
No approved-drug candidate for dyskeratosis congenita, autosomal recessive 5 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
telomerase reverse transcriptase (TERT) — TERT is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
RCSB Protein Data Bank · entry 9Q16 · 2.7 Å · ligand 2'-deoxy-5'-O-[(R)-hydroxy{[(R)-hydroxy(phosphonooxy)phosphoryl]amino}phosphoryl]guanosine (XG4). Experimental structure, not a prediction.
Dyskeratosis congenita is a rare hereditary bone marrow failure syndrome with X-linked recessive, autosomal dominant, and autosomal recessive inheritance patterns; in 30–40% of patients the inheritance pattern remains unknown. The classic mucocutaneous triad consists of abnormal skin pigmentation, nail dystrophy, and oral leukoplakia. Additional features include pulmonary fibrosis, liver fibrosis, predisposition to malignancy, and aplastic anaemia. A 1977 review of 46 previously reported cases plus a family spanning three generations with nine affected members noted pancytopenia of variable onset, opportunistic infections, and neoplasia as haematologic complications. A 2020 report describes Hoyeraal-Hreidarsson syndrome as a multisystem variant that presents with aplastic anaemia, cerebellar hypoplasia, and growth retardation, predominantly in males.
Two male patients in a Japanese kindred with an X-linked DKC1 missense mutation (L398P) showed markedly different haematological severity despite carrying the same mutation, indicating that factors beyond the primary gene defect modify disease expression. A 2022 case report of a 21-year-old male with sporadic dyskeratosis congenita describes the most benign presentation, but notes that patients are at higher risk of malignancies, pulmonary fibrosis, and eventual bone marrow failure as a cause of death. No treatment or drug intervention is discussed in any of these abstracts.
The abstracts provide no data on survival rates, response rates, or sample sizes beyond the 46-case review and single-family reports. No drug repurposing evidence appears in these abstracts. What remains missing is any prospective trial design, patient stratification by genetic subtype, or funding for systematic natural history studies that could support future therapeutic testing.
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractDyskeratosis congenita (DC) is a hereditary disorder characterized by mucocutaneous manifestations, bone marrow failure, predisposition to malignancy, pulmonary and liver fibrosis and additional features.[1][1] X-linked recessive, autosomal recessive and autosomal dominant (AD) forms of inheritance
https://doi.org/10.3324/haematol.12317AbstractDyskeratosis congenita is a rare genodermatosis whose hematologic complications include pancytopenia of variable time of onset, a propensity for opportunistic infections, and neoplasia. A family in which the disorder segregated in 3 generations and involved 9 members is reported, and the hematologic data of the 46 previously reported cases are reviewed.
https://doi.org/10.1002/ajh.2830030205AbstractThe authors report 2 male patients with dyskeratosis congenita (DC) in a Japanese kindred. Sequencing of the complementary DNA of the dyskerin gene (DKC1) revealed a T-to-C transition at nucleotide 1285 in exon 12 that resulted in a novel missense mutation L398P. Despite harboring the same mutation in the DKC1 gene, one patient had significantly milder hematological symptoms than the other, indicating that there may be other factors that determine the severity of DC.
https://doi.org/10.1080/08880010290097170AbstractDyskeratosis congenita (DC) is a rare disease and a genetic heterogeneity of bone marrow failure, characterized by muco-cutaneous triad of mucosal leukoplakia, abnormal skin pigmentation, nails dystrophy and often involving multiple organs or systems. The inheritance patterns of DC include X-linked recessive, autosomal dominant and recessive patterns. However, the inheritance patterns in 30%-40% of DC patients remained unknown. Dyskeratosis congenita is difficult to diagnose because of its genetic and clinical heterogeneity. This article will review and discuss the state-of-the-art progresses in genetics, clinical manifestation, diagnosis, differential diagnosis, treatment and prognosis of DC.
https://doi.org/10.3760/cma.j.issn.1002-0098.2019.02.010AbstractDyskeratosis congenita (DC) also known as Zinsser-Engman-Cole syndrome is very uncommon.The primary clinical features include oral leukoplakia, nail dystrophy, and reticular skin pigmentations.Hoyeraal-Hreidarsson syndrome (HH) is a variant of DC and has a multi system involvement.It commonly affects males and presents with aplastic anemia, multiple infections, cerebellar-hypoplasia and growth retardation.The etiology is unknown.
https://doi.org/10.38207/jmcrcs20201049AbstractDyskeratosis congenita was first described in 1960 as Zinsser-Engman-Cole syndrome. It is a rare inherited condition with a progressive nature and a tendency to involve multiple systems like pulmonary, gastrointestinal, genitourinary, cerebral, and dental. It has an X-linked recessive (most common) or Autosomal dominant or recessive inheritance with a high male preponderance. The genetic defect lies in the DKC1 gene which encodes for Dyskerin protein. Dyskeratosis congenita patients are at a higher risk of development of malignancies, pulmonary fibrosis and eventually aplastic anemia and bone marrow failure which may be the cause of death. This report details a case of Dyskeratosis congenita affecting a 21 year old male patient with the most benign presentation.
https://doi.org/10.18231/j.ijced.2022.012Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
